| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9835fd9ec52f7806c94fc23e9318241b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7a92329b87fd1ed1f33d6b879c9c6d83 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2833
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-249
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-082
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H21-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-08 |
| filingDate |
2004-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2013-01-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f03b9cd3387a2f75f9a200bb24159e35
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49032786577717e5943c75e101867edb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d46832914f72da1eab8157fa9f021f4d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac7c5b83b3fb41e8c6e82a5b5c1c130e |
| publicationDate |
2013-01-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2394088-T3 |
| titleOfInvention |
Alternate binding affinities for FCRN or serum simivides of antibodies by mutagenesis |
| abstract |
An antibody that is modified from daclizumab comprising glutamic acid or glutamine in amino acid residue 250 and leucine or phenylalanine in amino acid residue 428, and in which amino acid residues are numbered by the EU numbering system for use in prophylaxis or therapy, wherein a) the amino acid residue 250 of the constant region of the heavy chain is glutamic acid and the amino acid residue 428 of the constant region of the heavy chain is phenylalanine. b) amino acid residue 250 of the heavy chain constant region is glutamine and amino acid residue 428 of the heavy chain constant region is phenylalanine; or c) amino acid residue 250 of the heavy chain constant region is glutamine and amino acid residue 428 of the heavy chain constant region is leucine. |
| priorityDate |
2003-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |